Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.

Kang Y, Xie L, Tran DT, Stein CS, Hickey M, Davidson BL, McCray PB Jr.

Blood. 2005 Sep 1;106(5):1552-8. Epub 2005 May 10.

2.

Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.

Staber JM, Pollpeter MJ, Anderson CG, Burrascano M, Cooney AL, Sinn PL, Rutkowski DT, Raschke WC, McCray PB.

Gene Ther. 2017 Nov;24(11):742-748. doi: 10.1038/gt.2017.67. Epub 2017 Sep 14.

3.

In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.

Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB Jr, Davidson BL.

J Virol. 2002 Sep;76(18):9378-88.

4.

Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector.

Sinn PL, Goreham-Voss JD, Arias AC, Hickey MA, Maury W, Chikkanna-Gowda CP, McCray PB Jr.

Hum Gene Ther. 2007 Dec;18(12):1244-52.

PMID:
18052720
5.

In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors.

Stein CS, Kang Y, Sauter SL, Townsend K, Staber P, Derksen TA, Martins I, Qian J, Davidson BL, McCray PB Jr.

Mol Ther. 2001 Jun;3(6):850-6.

6.
7.

Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer.

Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB Jr.

J Virol. 2005 Oct;79(20):12818-27.

8.

Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.

Matsui H, Fujimoto N, Sasakawa N, Ohinata Y, Shima M, Yamanaka S, Sugimoto M, Hotta A.

PLoS One. 2014 Aug 15;9(8):e104957. doi: 10.1371/journal.pone.0104957. eCollection 2014.

9.

A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

Matsui H, Hegadorn C, Ozelo M, Burnett E, Tuttle A, Labelle A, McCray PB Jr, Naldini L, Brown B, Hough C, Lillicrap D.

Mol Ther. 2011 Apr;19(4):723-30. doi: 10.1038/mt.2010.290. Epub 2011 Feb 1.

11.

Efficient production of human FVIII in hemophilic mice using lentiviral vectors.

Kootstra NA, Matsumura R, Verma IM.

Mol Ther. 2003 May;7(5 Pt 1):623-31.

12.

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.

Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S.

Blood. 2003 Mar 1;101(5):1734-43. Epub 2002 Oct 24.

13.

Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.

VandenDriessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen ML, Collen D, Chuah MK.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10379-84.

14.

Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.

Johnston JM, Denning G, Doering CB, Spencer HT.

Gene Ther. 2013 Jun;20(6):607-15. doi: 10.1038/gt.2012.76. Epub 2012 Sep 20.

15.

Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.

Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D.

Stem Cells. 2007 Oct;25(10):2660-9. Epub 2007 Jul 5.

16.

In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.

Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S.

Hum Gene Ther. 1999 Jul 20;10(11):1791-802.

PMID:
10446919
17.

Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.

Connelly S, Andrews JL, Gallo-Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M.

Thromb Haemost. 1999 Feb;81(2):234-9.

PMID:
10063998
18.

Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.

Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S.

Hum Gene Ther. 2001 Sep 1;12(13):1651-61.

PMID:
11535168
19.

Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.

Nambiar B, Cornell Sookdeo C, Berthelette P, Jackson R, Piraino S, Burnham B, Nass S, Souza D, O'Riordan CR, Vincent KA, Cheng SH, Armentano D, Kyostio-Moore S.

Hum Gene Ther Methods. 2017 Feb;28(1):23-38. doi: 10.1089/hgtb.2016.124.

20.

Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.

Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW.

PLoS One. 2012;7(5):e37671. doi: 10.1371/journal.pone.0037671. Epub 2012 May 24.

Supplemental Content

Support Center